Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that prompt hair removal effectively treated hair tourniquet syndrome in infants, with all patients healing without complications.

This study analyzed the features of alopecia areata incognita and diffuse alopecia areata, finding distinct patterns in hair loss regions and trichoscopic signs, and noted a benign course responsive to topical steroid therapy.

This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.

This study suggests that in alopecia areata, innate lymphoid cells type 1 may contribute to the disease’s pathogenesis by inducing hair follicle changes similarly to CD8+ T cells.

This study found that at Week 52, baricitinib resulted in significant hair regrowth for many patients with severe alopecia areata, with 41.6% on the higher dose achieving substantial improvement in scalp hair loss, though some may need longer treatment for optimal benefit.

This review discusses the relationship between allergies and alopecia areata, highlighting potential roles for anti-allergy and desensitization therapies, but reports no new clinical results.

This case report describes successful treatment of anaplasmosis in a Kintamani mix dog with doxycycline, ivermectin, vetadryl, and Livron b-plex, leading to improved activity, hair growth, appetite, and tick eradication.

This study reports a unique case of identical twins experiencing alopecia areata at the same time, suggesting potential environmental triggers for this polygenic autoimmune condition.

This report describes two cases of tinea capitis: one resistant to local iodine treatment after partial improvement, and another cured with the same treatment, in African American and Caucasian children, respectively.

This case report found that oral tofacitinib treatment resulted in more than 90% hair regrowth in a 6-year-old with severe alopecia areata, with no relapse after dose reduction.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

This case study highlights a patient with alopecia areata who experienced telogen effluvium after regrowth following diphencyprone-induced contact dermatitis.

This study found that after 24 weeks of DPCP treatment for alopecia areata, there was a significant increase in new capillaries and hair regrowth detectable by videocapillaroscopy.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

In this study, researchers observed that telogen hair was more prevalent than anagen hair in both male and female agoutis over a one-year period in Teresina-PI, regardless of dry or rainy seasons, with no significant differences in dermal follicular volume between the sexes.

This article reviews treatment options for pityriasis rubra pilaris but reports no new clinical findings, often noting treatments as unsuccessful.

This study demonstrated that AtVLN4 plays a role in root hair growth by regulating actin organization in a calcium-dependent manner.

This study reported that dithranol treatment up to 3% concentration led to hair regrowth in alopecia areata patients who had previously failed ultra-potent steroids, with regrowth observed across all severity levels.

Alopecia areata patients often have low vitamin D levels.

This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.

Photographic documentation crucial for evaluating hair growth in androgenetic alopecia.

This research highlights that JAK inhibitors, such as baricitinib, may effectively reverse symptoms of alopecia areata by targeting specific immune pathways, though safety and efficacy require further investigation.

Men with Addison disease should be screened for X-linked adrenoleukodystrophy if they have hair loss.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

This study found that anagen stage protein homogenates and specific epitopes from melanogenesis proteins activated CD8 T cells, suggesting alopecia areata is an anagen-specific disease.

This study found that the DFS pattern occurs in about 28% of ANA-positive cases and is relatively frequent in autoimmune diseases, contrary to previous observations suggesting no link with these diseases.

AGC2-1 protein is essential for root hair growth in Arabidopsis.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

This article discusses hair loss disorders, underscoring the recent therapeutic advance of ritlecitinib, approved for severe alopecia areata in individuals aged 12 and older, and the ongoing need to manage expectations given limited treatment options.